At a glance
ClinicalIndex Comparison RecordPhase 3Completed
Drug / intervention
MK0733 / Duration of Treatment: 18 Weeks +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Balanced, Three-Way Crossover Study to Evaluate the Efficacy of Simvastatin Therapy in Elevating HDL-C Levels in Patients With Type 2 Diabetic Dyslipidemia and Low HDL-C
In Brief
A Phase 3 clinical trial evaluating MK0733 / Duration of Treatment: 18 Weeks and Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks for HDL Cholesterol. Completed.
Detailed Summary
The purpose of this study is to see how well simvastatin raises HDL levels in patients with Type 2 Diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHDL Cholesterol
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2001
Primary CompletionOct 2002
First PostedOct 2006
TodayJul 2026
First PostedOct 19, 2006
Enrollment StartJul 26, 2001
Primary CompletionOct 4, 2002
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.7 years ago
Interventions
MK0733 / Duration of Treatment: 18 Weeksdrug
Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeksdrug